TY - JOUR
T1 - Granulocytic Sarcoma:Potential Diagnostic Clues From Immunostaining Patterns Seen With Anti-Lymphoid Antibodies
AU - Goldstein, Neal S.
AU - Ritter, Jon H.
AU - Argenyi, Zsolt B.
AU - Wick, Mark R.
PY - 1995/1
Y1 - 1995/1
N2 - Because of shared histologic and clinical features, granulocytic sarcoma (GS) may be confused with B- and T cell malignant lymphomas. Antibodies to myeloperoxidase, lysozyme, CD 15, and other determinants may correctly identify GS but are usually not part of the standard panels employed to evaluate a suspected non-Hodgkin's lym phoma. At the authors' institutions, these typically include reagents to CD20, CD43, CD45, CD45RO, and MB2. In this analysis, well-documented cases of GS and histologi cally similar lymphomas were assessed using a standard immunohistologic antibody panel employed in evaluation of putative lymphomas. In addition, antibodies to lyso zyme, myeloperoxidase, CD3, CD15, CD34, CD68, and MAC 387 were used in a second tier of analysis. The results were evaluated in a step-wise fashion. All B cell lymphomas and the majority of T cell cases were identified correctly by their reactivity for CD20 and CD45RO, respectively. Using the five standard lymphomas markers, 12 of 19 cases of GS had a phenotype that would be relatively unusual in non-Hodgkin's lymphoma—as reflected by CD43 and MB2 coexpression without CD20 or CD45RO-whereas 7 cases of GS showed a “CD43-only” phenotype and were there fore considered possible T cell lesions. All 19 GS cases were labeled by at least one second-tier marker and 18 exhibited two or more of these determinants at that level of evaluation. All T cell lymphomas failed to express CD 15, CD34, CD68, or MAC 387; however, 3 of 20 B cell tumors were focally positive for CD 15. CD3 labeled 9 of 11 cases of T cell lymphoma but also was seen in 11 of 16 cases of GS. These results indicate that, in suspected lymphoma cases, CD45-positivity, but failure to express CD20 or CD45RO, suggests the possibility of GS. Additional immunohistologic studies, in particular those for lysozyme or myeloperoxidase, can then be used to further define the tumoral lineage. Int J Surg Pathol 2(3):177-186, 1995
AB - Because of shared histologic and clinical features, granulocytic sarcoma (GS) may be confused with B- and T cell malignant lymphomas. Antibodies to myeloperoxidase, lysozyme, CD 15, and other determinants may correctly identify GS but are usually not part of the standard panels employed to evaluate a suspected non-Hodgkin's lym phoma. At the authors' institutions, these typically include reagents to CD20, CD43, CD45, CD45RO, and MB2. In this analysis, well-documented cases of GS and histologi cally similar lymphomas were assessed using a standard immunohistologic antibody panel employed in evaluation of putative lymphomas. In addition, antibodies to lyso zyme, myeloperoxidase, CD3, CD15, CD34, CD68, and MAC 387 were used in a second tier of analysis. The results were evaluated in a step-wise fashion. All B cell lymphomas and the majority of T cell cases were identified correctly by their reactivity for CD20 and CD45RO, respectively. Using the five standard lymphomas markers, 12 of 19 cases of GS had a phenotype that would be relatively unusual in non-Hodgkin's lymphoma—as reflected by CD43 and MB2 coexpression without CD20 or CD45RO-whereas 7 cases of GS showed a “CD43-only” phenotype and were there fore considered possible T cell lesions. All 19 GS cases were labeled by at least one second-tier marker and 18 exhibited two or more of these determinants at that level of evaluation. All T cell lymphomas failed to express CD 15, CD34, CD68, or MAC 387; however, 3 of 20 B cell tumors were focally positive for CD 15. CD3 labeled 9 of 11 cases of T cell lymphoma but also was seen in 11 of 16 cases of GS. These results indicate that, in suspected lymphoma cases, CD45-positivity, but failure to express CD20 or CD45RO, suggests the possibility of GS. Additional immunohistologic studies, in particular those for lysozyme or myeloperoxidase, can then be used to further define the tumoral lineage. Int J Surg Pathol 2(3):177-186, 1995
KW - acute myelogenous leukemia
KW - granulocytic sarcoma
KW - hematopoietic neo plasms
KW - immunohistology
KW - non-Hodgkin's lymphoma
UR - http://www.scopus.com/inward/record.url?scp=0028821165&partnerID=8YFLogxK
U2 - 10.1177/106689699500200302
DO - 10.1177/106689699500200302
M3 - Article
AN - SCOPUS:0028821165
SN - 1066-8969
VL - 2
SP - 177
EP - 186
JO - International Journal of Surgical Pathology
JF - International Journal of Surgical Pathology
IS - 3
ER -